Item 1.01
|
Entry into a Material Definitive Agreement.
|
On October 17, 2017, Neothetics, Inc.
(
Neothetics
or the
Company
), Nobelli Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Neothetics (
Merger Sub
), and Evofem Biosciences, Inc., a privately-held Delaware
corporation (
Evofem
), entered into an Agreement and Plan of Merger and Reorganization (the
Merger Agreement
), pursuant to which, among other things, subject to the satisfaction or waiver of the conditions set
forth in the Merger Agreement, Merger Sub will merge with and into Evofem, with Evofem becoming a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the
Merger
). The Merger is intended to qualify
for federal income tax purposes as a
tax-free
reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended.
Immediately prior to the effective time of the Merger (the
Effective Time
), each outstanding share of Evofems
preferred stock (other than shares of Evofems Series D preferred stock) will be converted into one share of Evofem common stock. Subject to the terms and conditions of the Merger Agreement, at the Effective Time: (a) each share of Evofem
common stock (on an
as-converted
basis) will be converted solely into the right to receive shares of the Companys common stock (the
Company
Common Stock
) equal to the common
stock exchange ratio described in the Merger Agreement; (b) each outstanding shares of Evofem Series D preferred stock will be converted solely into the right to receive shares of the Company Common Stock equal to the Series D preferred stock
exchange ratio described in the Merger Agreement; and (c) each outstanding Evofem stock option that has not previously been exercised prior to the Effective Time will be assumed by the Company. Warrants to purchase shares of Evofem capital
stock will be assumed by the Company at the Effective Time and then immediately amended and restated to become warrants to purchase up to an aggregate of 12 million shares of the Company Common Stock (the
Company Post-Merger
Warrants
). The exercise price for the Company Post-Merger Warrants will be equal to the average of the closing sale prices of the Company Common Stock as quoted on The NASDAQ Capital Market for the 30 consecutive trading day period
commencing with the first trading day immediately following the first public announcement of the Merger, or October 18, 2017.
Under
the exchange ratio formulas in the Merger Agreement, as of immediately after the Merger, and including the effect of the Financing (as defined below), the former Evofem securityholders are expected to own approximately 87% of the aggregate number of
shares of the issued and outstanding Company Common Stock (the
Post-Closing Shares
), and the stockholders of the Company as of immediately prior to the Merger are expected to own approximately 13% of the aggregate number of
Post-Closing Shares. The common stock exchange ratio and Series D preferred stock exchange ratio are subject to adjustment as set forth in Section 1.12(b) of the Merger Agreement.
Immediately following the Merger, the name of the Company will be changed from Neothetics, Inc. to Evofem Biosciences,
Inc. The Merger Agreement contemplates that the Board of Directors of the Company will consist of seven members at the Effective Time, six of which will be designated by Evofem and one of which will be designated by the Company. The member to
be designated by the Company is expected to be one of the current directors of the Company. The executive officers of the Company immediately after the Effective Time will be designated by Evofem with Evofems Chief Executive Officer, Saundra
Pelletier, being the Companys Chief Executive Officer.
The Merger Agreement contains customary representations, warranties and
covenants made by the Company and Evofem, including covenants relating to obtaining the requisite approvals of the stockholders of the Company and Evofem, indemnification of directors and officers, the Companys and Evofems conduct of
their respective businesses between the date of signing the Merger Agreement and the closing of the Merger. Consummation of the Merger is subject to certain closing conditions, including, among other things, approval by the stockholders of the
Company and Evofem. The Merger Agreement contains certain termination rights for both the Company and Evofem, and further provides that, upon termination of the Merger Agreement under specified circumstances, the Company may be required to pay
Evofem a termination fee of up to $1.5 million or Evofem may be required to pay the Company a termination fee of $1.5 million.
The Merger Agreement contemplates that the Company will also seek approval from its stockholders to effect a reverse stock split intended to
increase its trading price above the minimum requirements of The NASDAQ Capital Market. Subject to stockholder approval, the Company expects to implement the reverse stock split at a ratio to be mutually agreed to by the Company and Evofem within
the range approved by the Companys stockholders immediately prior to the Effective Time.
In accordance with the terms of the Merger
Agreement, certain affiliated stockholders of Evofem have each entered into a support agreement with Evofem (the
Support Agreements
). The Support Agreements place certain restrictions on the transfer of the shares of Evofem held
by the respective signatories thereto and include covenants as to the voting of such shares in favor of approving the transactions contemplated by the Merger Agreement and against any actions that could adversely affect the consummation of the
Merger.
Concurrently with the execution of the Merger Agreement, certain officers and directors of Evofem, each entered into
lock-up
agreements (the
Lock-Up
Agreements
) pursuant to which they have agreed, among other things, not to sell or dispose of any shares
of Company Common Stock which are or will be beneficially owned by them at the closing of the Merger until 180 days following the Effective Time.
Concurrently with the execution of the Merger Agreement, the Company entered into a Securities Purchase Agreement with Evofem and certain
investors of Evofem (the
Securities Purchase Agreement
) pursuant to which, conditioned upon and immediately following the Merger, the Company will issue and sell in a private placement transaction (the
Financing
) $20 million of Company Common Stock and Evofem will issue warrants to purchase shares of Evofem common stock immediately prior to the Effective Time (the
Investor Warrants
). The Investor Warrants
will be automatically exercised on a cashless basis at the Effective Time, and the shares of Evofem common stock issued upon exercise of the Investor Warrant will be eligible to receive shares of the Company Common Stock in an amount equal to the
common stock exchange ratio upon completion of the Merger. Upon consummation of the Financing, the Company will terminate its existing Fourth Amended and Restated Investors Rights Agreement, dated September 22, 2014, by and between the
Registrant and the investors listed therein (the
Existing Investors
), and enter into a registration rights agreement with certain of the Existing Investors and certain investors of Evofem.
The Merger Agreement, form of Support Agreement, form of
Lock-Up
Agreement and the Securities Purchase
Agreement have each been included as an exhibit to this Current Report to provide the Companys stockholders with information regarding their terms. The assertions embodied in the representations and warranties contained in the Merger Agreement
are qualified by information in confidential disclosure schedules delivered by the parties in connection with the signing of the Merger Agreement. Moreover, certain representations and warranties contained in these agreements were made as of a
specified date; may have been made for the purposes of allocating contractual risk between the parties to such agreements; and may be subject to contractual standards of materiality different from what might be viewed as material to the
Companys stockholders. Accordingly, the representations and warranties in these agreements should not be relied on by any persons as characterizations of the actual state of facts and circumstances of the Company or any other parties thereto
at the time they were made and should consider the information in these agreements in conjunction with the entirety of the factual disclosure about the Company in the Companys public reports filed with the Securities and Exchange Commission,
or the SEC. Information concerning the subject matter of the representations and warranties may change after the date of these agreements, which subsequent information may or may not be fully reflected in the Companys public disclosures. These
agreements should not be read alone, but should instead be read in conjunction with each other and other information regarding the Company.
The preceding summary does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, the form of
Support Agreement, the form of
Lock-up
Agreements and the Securities Purchase Agreement, which are filed as Exhibits 2.1, 2.2, 10.1 and 10.2, respectively, and which are incorporated herein by reference.